Anticonvulsants

OVID Provides Update on OV101 Program and the Prioritization of its Resources

Retrieved on: 
Monday, April 19, 2021
Branches of biology, Neurochemistry, Anticonvulsants, Gaboxadol, Sedatives, Neurological disorders, Angelman syndrome, GABAA receptor, XC2

As part of this update, Ovid will discontinue development of OV101 (gaboxadol), a delta (\xce\xb4)-selective GABAA\xc2\xa0receptor agonist, in Angelman syndrome.

Key Points: 
  • As part of this update, Ovid will discontinue development of OV101 (gaboxadol), a delta (\xce\xb4)-selective GABAA\xc2\xa0receptor agonist, in Angelman syndrome.
  • Furthermore, Ovid does not plan to initiate further clinical studies of OV101 in Fragile X syndrome.
  • \xe2\x80\x9cWhile we are disappointed in the outcome for OV101, our resources are now squarely focused on a very promising pipeline in rare neurological diseases, including Angelman syndrome.
  • Ovid assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.\n'

Novadoz Has a Fast Start to 2021 with Generic Launches of Albendazole, Droxidopa, Deferasirox Granules, and Pregabalin ER

Retrieved on: 
Friday, April 23, 2021
Pharmacology, Euphoriants, Health sciences, Analgesics, Anticonvulsants, Anxiolytics, Pregabalin, MSN Dial-up, Brand, Tablet, Health care

Novadoz is the U.S sales and marketing affiliate for MSN\'s portfolio of finished dosage forms.

Key Points: 
  • Novadoz is the U.S sales and marketing affiliate for MSN\'s portfolio of finished dosage forms.
  • The company has commenced shipping of all the products which received approvals during Q1 2021.\nAlbendazole 200mg is marketed in bottles of 2 tablets.
  • Novadoz participated in a Day 1 launch of the product, coinciding with the expiration of the brand exclusivity.
  • The other niche offering includes Pregabalin ER 82.5mg, 165mg, and 330mg tablets available in bottles of 30.

Dragonfly Biosciences Launches Global Outreach Into Australia

Retrieved on: 
Thursday, April 22, 2021
Drugs, Arthropods, Hexapoda, Analgesics, Anticonvulsants, Cannabidiol, Cannabinoids, Resorcinols, Dragonfly

b'LONDON, April 22, 2021 /PRNewswire/ -- Dragonfly Biosciences UK , makers of a leading seed to shelf range of CBD oils and skincare products has formed a non-exclusive distribution agreement with Health House International Australia, enabling the sale of Dragonfly CBD oils over the counter in Australia.

Key Points: 
  • b'LONDON, April 22, 2021 /PRNewswire/ -- Dragonfly Biosciences UK , makers of a leading seed to shelf range of CBD oils and skincare products has formed a non-exclusive distribution agreement with Health House International Australia, enabling the sale of Dragonfly CBD oils over the counter in Australia.
  • The partnership comes off the back of the Australian Therapeutic Goods Administration in February 2021 changing the regulations to allow registered CBD products to be sold over the counter in Australian Pharmacies.\nCommenting on the partnership with Health House International Australia, Regan Saveall, Chief Executive at Dragonfly Biosciences UK says:"The non-exclusive distribution agreement with Health House International is great news for Dragonfly Biosciences and more importantly our range of CBD products as we extend our global outreach to shoppers in Australia.
  • The Dragonfly CBD brand is sold in thousands of pharmacies and grocery retailers already.
  • "\nRegan Saveall, Chief Executive at Dragonfly Biosciences UK notes further:"Sharing the same business values is essential for any working partnership.

Dragonfly Biosciences Launches Global Outreach Into Australia

Retrieved on: 
Thursday, April 22, 2021
Drugs, Arthropods, Hexapoda, Analgesics, Anticonvulsants, Cannabidiol, Cannabinoids, Resorcinols, Dragonfly

b'LONDON, April 22, 2021 /PRNewswire/ -- Dragonfly Biosciences UK , makers of a leading seed to shelf range of CBD oils and skincare products has formed a non-exclusive distribution agreement with Health House International Australia, enabling the sale of Dragonfly CBD oils over the counter in Australia.

Key Points: 
  • b'LONDON, April 22, 2021 /PRNewswire/ -- Dragonfly Biosciences UK , makers of a leading seed to shelf range of CBD oils and skincare products has formed a non-exclusive distribution agreement with Health House International Australia, enabling the sale of Dragonfly CBD oils over the counter in Australia.
  • The partnership comes off the back of the Australian Therapeutic Goods Administration in February 2021 changing the regulations to allow registered CBD products to be sold over the counter in Australian Pharmacies.\nCommenting on the partnership with Health House International Australia, Regan Saveall, Chief Executive at Dragonfly Biosciences UK says:"The non-exclusive distribution agreement with Health House International is great news for Dragonfly Biosciences and more importantly our range of CBD products as we extend our global outreach to shoppers in Australia.
  • The Dragonfly CBD brand is sold in thousands of pharmacies and grocery retailers already.
  • "\nRegan Saveall, Chief Executive at Dragonfly Biosciences UK notes further:"Sharing the same business values is essential for any working partnership.

Marinus Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, April 12, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Anticonvulsants, GABAA receptor positive allosteric modulators, Ketones, Neurosteroids, Sterols, Chemical compounds, Ganaxolone, Chemistry

b'Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (the \xe2\x80\x9cCompany\xe2\x80\x9d or \xe2\x80\x9cMarinus\xe2\x80\x9d), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the grant of an inducement award to Steven Pfanstiel, Marinus\xe2\x80\x99 newly-hired Chief Financial Officer and Treasurer.

Key Points: 
  • b'Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (the \xe2\x80\x9cCompany\xe2\x80\x9d or \xe2\x80\x9cMarinus\xe2\x80\x9d), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the grant of an inducement award to Steven Pfanstiel, Marinus\xe2\x80\x99 newly-hired Chief Financial Officer and Treasurer.
  • The stock option was granted as an inducement material to Mr. Pfanstiel entering into employment with Marinus in accordance with Nasdaq Listing Rule 5635(c)(4), and is subject to the terms and conditions of the award agreement covering such grant.\nMarinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
  • Marinus undertakes no obligation to update or revise any forward-looking statements.

SK life science Reports Effectiveness of Long-Term Use with Cenobamate

Retrieved on: 
Thursday, April 15, 2021
Life sciences, Health sciences, Health, Chaebol, SK Group, Pharmaceutical industry, Anticonvulsants, GABAA receptor positive allosteric modulators, Sodium channel blockers, Biopharmaceutical, Pharmaceutical industry in India, Phenytoin

The objectives of the study included the characterization of the long-term safety of cenobamate and to understand how to best add cenobamate to regimens that included phenytoin or phenobarbital.

Key Points: 
  • The objectives of the study included the characterization of the long-term safety of cenobamate and to understand how to best add cenobamate to regimens that included phenytoin or phenobarbital.
  • Further increases to 400 mg/day using bi-weekly 50 mg/day increments were allowed.\nCenobamate was discovered and developed by SK Biopharmaceuticals and SK life science.
  • For more information, visit SK Biopharmaceuticals\' website at www.skbp.com/eng and SK life science\'s website at www.SKLifeScienceInc.com .\nBoth SK Biopharmaceuticals and SK life science are part of SK Group, one of the largest conglomerates in Korea.
  • SK Inc., the parent company of SK Biopharmaceuticals, continues to enhance its portfolio value by executing long-term investments witha number ofcompetitive subsidiaries in various business areas, including pharmaceuticals and life science, energy and chemicals, information and telecommunication, and semiconductors.

New THC-Free, High-End CBD Brand Naturally Enhances Beauty

Retrieved on: 
Friday, April 2, 2021
Drugs, Branches of biology, Orphan drugs, Pharmacology, Circadian rhythm, Treatment of bipolar disorder, Analgesics, Anticonvulsants, Cannabidiol, Melatonin, Sleep, Softgel

As CBD regulations ease and the product becomes more mainstream, consumers are discovering the benefits of CBD, including for beauty.

Key Points: 
  • As CBD regulations ease and the product becomes more mainstream, consumers are discovering the benefits of CBD, including for beauty.
  • The Imaginal product line includes:
    Everyday Softgel - All the benefits of CBD in an easy-to-swallow soft gel that allows your body to absorb CBD faster.
  • Melatonin Softgel - The Imaginal Sleep Formula soft gels combine CBD with melatonin, a naturally occurring sleep hormone, to ensure that you get a peaceful night's sleep.
  • "I originally incorporated CBD oil to improve a chronic health condition, but I quickly saw the benefits of CBD to improve overall health and wellness, including beauty," explains co-founder Jessica Kerr.

Arrive Market Welcomes KANA Skincare to Its Curated, High-Quality CBD Marketplace

Retrieved on: 
Tuesday, March 30, 2021
Drugs, Analgesics, Anticonvulsants, Cannabidiol, Cannabinoids, Resorcinols, Online marketplace, Organ systems

LOS ANGELES, March 30, 2021 /PRNewswire/ -- Arrive Market , a new online marketplace for high-quality, lab-tested cannabidiol (CBD) products, brings on KANA Skincare , an innovative company that creates clean, high-performance skincare products harnessing the power of K-Beauty, aromatherapy, and CBD to bring tangible results to consumers.

Key Points: 
  • LOS ANGELES, March 30, 2021 /PRNewswire/ -- Arrive Market , a new online marketplace for high-quality, lab-tested cannabidiol (CBD) products, brings on KANA Skincare , an innovative company that creates clean, high-performance skincare products harnessing the power of K-Beauty, aromatherapy, and CBD to bring tangible results to consumers.
  • "We started Arrive Market to establish a curated selection of brands to help consumers easily discover the highest-quality, lab-tested CBD products on the market," said Emily Lee, co-founder and Director of Marketing for Arrive Market.
  • "When we were looking for a new partner to grow the KANA Skincare brand, Arrive Market was the clear choice," said Janice Buu, founder ofKANA Skincare.
  • 'Arrive Market is a newly launched online CBD marketplace for high-quality, lab-tested products, transforming the wellness shopping experience for consumers.

SMPLSTC Reveals 3 New CBD Tinctures

Retrieved on: 
Monday, March 29, 2021
Drugs, Pharmacology, Health care, Cannabis smoking, Cannabinoids, Euphoriants, Entheogens, Anticonvulsants, Cannabidiol, Cannabis, Fragrance extraction, Tincture

Each CBd tincture includes CO2 extracted CBD oil for a superior product.

Key Points: 
  • Each CBd tincture includes CO2 extracted CBD oil for a superior product.
  • CBD oils that are extracted with the CO2 extraction method are solvent-free and free of unwanted chemicals or plant matter.
  • Shop CBD with SMPLSTC and discover products crafted with your best interest in mind.
  • Browse the shop to find a line of high-quality CBD oil tinctures, CBD topicals, CBD edibles, CBD capsules, or CBD pre-rolled joints.

The CBD Brand Focused on Family

Retrieved on: 
Friday, March 26, 2021
Drugs, Cannabinoids, Resorcinols, Natural phenols, Anticonvulsants, Cannabidiol, CBD, Customer base

FORT LAUDERDALE, Fla., March 26, 2021 /PRNewswire/ --CBD startup Zero In On Nutrition is more than just another brand in the flourishing cannabidiol industry.

Key Points: 
  • FORT LAUDERDALE, Fla., March 26, 2021 /PRNewswire/ --CBD startup Zero In On Nutrition is more than just another brand in the flourishing cannabidiol industry.
  • It is a company that is built on family, is focused on community, and is seeking genuine holistic solutions for its rapidly expanding customer base.
  • At least, that's how entrepreneur Rocco DiPietro felt when he launched his CBD brand Zero In On Nutrition.
  • The goal was simple: to invite their customers into the "family fold," so to speak, by producing the absolute highest quality CBD products on the market.